

Concise Formal Total Synthesis of Platensimycin Mediated by a Stereoselective Autoxidation and Hydroxyl Group Directed Conjugative Reduction


Philip Magnus,* Heriberto Rivera, and Vince Lynch†

Department of Chemistry and Biochemistry, University of Texas at Austin,
1 University Station A5300, Austin, Texas 78712-1167, United States

p.magnus@mail.utexas.edu

Received October 21, 2010

ABSTRACT



The synthesis of **13**, an advanced intermediate in the Nicolaou synthesis of platensimycin **1**, was made from **9** by autoxidation to give **10**, which was stereoselectively reduced providing **12**. Finally, dehydration of **12** by heating in DMSO resulted in **13**.

The structure¹ and broad spectrum antimicrobial activity² of platensimycin **1** has rapidly attracted considerable attention from the organic synthesis community.³ The retrosynthesis for **1** involves the cross-conjugated 2,5-cyclohexadienone **2** formed from the intramolecular carbenoid insertion of **3**, Figure 1.⁴ The acid **4** is available in both R- and S-enantiomeric enriched forms from the microbial reduction




Figure 1. Retrosynthetic analysis of platensimycin **1**.

of the corresponding 1-tetralone-2-carboxyethyl esters followed by hydrogenolysis of the benzylic hydroxyl group.⁵


The recent reports by Mulzer^{3i,t} and Corey^{3j} concerning the conversion of **2** into **6**, and **5** into **6** respectively, and the subsequent reduction of **6** and dehydrogenation to give **7** as a mixture of stereoisomers at C-9 (40:1, Mulzer), a pivotal intermediate in the Nicolaou synthesis of both (±)-**1**^{3a} and

† Author for inquiries concerning the X-ray data.

(1) (a) Singh, S. B.; Jayasuriya, H.; Ondeyka, J. G.; Herath, K. B.; Zhang, C.; Zink, D. L.; Tsou, N. N.; Ball, R. G.; Basilio, A.; Genilloud, O.; Diez, M. T.; Vicente, F.; Pelaez, F.; Young, K.; Wang, J. *J. Am. Chem. Soc.* **2006**, *128*, 11916–11920. (b) Singh, S. B.; Herath, K. B.; Wang, J.; Tsou, N.; Ball, R. G. *Tetrahedron Lett.* **2007**, *48*, 5429–5433.

(2) (a) Wang, J.; Soisson, S. M.; Young, K.; Shoop, W.; Kodali, S.; Galgoci, A.; Painter, R.; Parthasarathy, G.; Tang, Y. S.; Cummings, R.; Ha, S.; Dorso, K.; Motyl, M.; Jayasuriya, H.; Ondeyka, J.; Herath, K.; Zhang, C.; Hernandez, L.; Allocco, J.; Basilio, A.; Tormo, J. R.; Genilloud, O.; Vicente, F.; Pelaez, F.; Colwell, L.; Lee, S. Ho.; Michael, B.; Felcetto, T.; Gill, C.; Silver, L. L.; Hermes, J. D.; Bartizal, K.; Barrett, J.; Schmatz, D.; Becker, J. W.; Cully, D.; Singh, S. B. *Nature* **2006**, *441*, 358–361. (b) Brown, E. D. *Nature* **2006**, *441*, 293–294. (c) Pearson, H. *Nature* **2006**, *441*, 260–261. (d) Holzgrabe, U.; Dingermann, T.; Zundorf, I. *Pharmazie in unserer Zeit* **2006**, *35*, 388–389. (e) Habich, D.; von Nussbaum, F. *Chem. Med. Chem.* **2006**, *1*, 951–954. (f) Nicolaou, K. C.; Stepan, A. F.; Lister, T.; Li, A. G.; Montero, A.; Tria, G. S.; Turner, C. I.; Tang, Y.; Wang, J.; Denton, R. M.; Edmonds, D. J. *J. Am. Chem. Soc.* **2008**, *130*, 13110–13119.

Scheme 1. Mulzer's and Corey's Route To form **6** and **7**^a




^a Reaction conditions: (a) MeMgI, THF, $-78\text{ }^{\circ}\text{C}$, 4 h (71% brsm); (b) NBS, (BzO)₂, CCl₄, reflux (75%); (c) NaOMe, THF, $0\text{ }^{\circ}\text{C}$ (80%); (d) *n*-Bu₄NF, THF, $130\text{ }^{\circ}\text{C}$ (88%); (e) Mulzer's conditions: (i) cat. Ir-cat **1**,^{3t} H₂, 84%; (ii) HIO₃/DMSO, DMSO, cyclohexene (60%), 1.3:1 epimers at C-9 (major isomer shown); (f) Corey's conditions: (i) [Rh(cod)₂]BF₄·(*R,R*)-DIOP, H₂ 600 psi (72%); (ii) TMSOTf, Me₃N, followed by IBX, MPO, DMSO (80%) (small amount of C-9 epimer).

(-)-**1**,^{3b} Scheme 1, prompted this report. In this letter we describe the use of **2** as a key intermediate in the formal total synthesis of platensimycin **1** that avoids the above strategy and leads to **13** (Scheme 3) in a completely stereoselective sequence.

We have explored an alkylation and autoxidation strategy as depicted in Scheme 2. The final product **10** only requires a hydroxyl directed stereospecific conjugated reduction of the tetrasubstituted dienone double bond, followed by formation of the tetrahydrofuran ring to complete a formal synthesis of platensimycin.^{3a,b}

Treatment of **2** with MeMgCl (3.0 equiv) in THF at $-78\text{ }^{\circ}\text{C}$ resulted in the complete consumption of **2** and the

Scheme 2. C-4 Alkylation and C-10 Autoxidation



formation of **8** (63%).³ⁱ Whereas, treatment of **2** with MeLi (excess) in THF at $-78\text{ }^{\circ}\text{C}$ also gave **8** (ca. 30%) along with recovered **2**. Quenching the above reaction at $-78\text{ }^{\circ}\text{C}$ with D₂O resulted in the incorporation of one deuterium atom α -to the cyclopentanone carbonyl group in recovered **2**, thus indicating, as suspected, that enolization of **2** by MeLi is the deleterious pathway that drastically reduces the yield of **8**.

Treatment of **8** with *t*-BuOK/*t*-BuOH/MeI gave **9** (61%), with no detectable amounts of any geminal dimethylation product. It was found that exposure of **9** to O₂ and *n*-Bu₄NBr/KOH/H₂O/*t*-BuOH^{6,7} gave **10** (65%) as a single stereoisomer whose structure was established by single X-ray crystallography, Figure 2. When the autoxidation process was




Figure 2. ORTEP of **10**.

conducted at $-78\text{ }^{\circ}\text{C}$ in the presence of P(OMe)₃, the α -hydroxyenone **11** (8%) was also isolated. It appears likely that **10** arises from **11a** by rearrangement of the intermediate

(6) For autoxidation of saturated ketones, see: (a) Bailey, E. J.; Barton, D. H. R.; Elks, J.; Templeton, J. F. *J. Chem. Soc.* **1962**, 1578–1591. (b) Gardner, J. N.; Carlton, F. E.; Gnoj, O. *J. Org. Chem.* **1968**, *33*, 3294–3297. (c) Wender, P. A.; Mucciario, T. P. *J. Am. Chem. Soc.* **1992**, *114*, 5878–5879. (d) Magnus, P.; Ujjainwalla, F.; Westwood, N.; Lynch, V. *Tetrahedron* **1998**, *54*, 3069–3092.

(7) For autoxidation of α,β -unsaturated ketones, see: (a) Shimizu, T.; Hiranuma, S.; Yoshioka, H. *Chem. Pharm. Bull.* **1989**, *37*, 1963–1965. (b) Aladro, F. J.; Guerro, F. M.; Moreno-Dorado, F. X.; Bustamante, J. M.; Jorge, Z. D.; Massanet, G. M. *Tetrahedron* **2001**, *57*, 2171–2178.

(3) (a) Nicolaou, K. C.; Li, A.; Edmonds, D. *J. Angew. Chem., Int. Ed.* **2006**, *45*, 7086–7090. (b) Nicolaou, K. C.; Edmonds, D. J.; Li, A.; Tria, G. S. *Angew. Chem., Int. Ed.* **2007**, *46*, 3942–3945. (c) Nicolaou, K. C.; Lister, T.; Denton, R. M.; Montero, A.; Edmonds, D. *J. Angew. Chem., Int. Ed.* **2007**, *46*, 4712–4714. (d) Nicolaou, K. C.; Tang, Y.; Wang, J. *Chem. Commun.* **2007**, *19*, 1922–1923. (e) Zou, Y.; Chen, C.-H.; Taylor, C. D.; Foxman, B. M.; Snider, B. B. *Org. Lett.* **2007**, *9*, 1825–1828. (f) Li, P.; Payette, J. N.; Yamamoto, H. *J. Am. Chem. Soc.* **2007**, *129*, 9534–9535. (g) Kaliappan, K. P.; Ravikumar, V. *Org. Lett.* **2007**, *9*, 2417–2419. (h) Ghosh, A. K.; Kai, X. *Org. Lett.* **2007**, *9*, 4013–4016. (i) Tiefenbacher, K.; Mulzer, J. *Angew. Chem., Int. Ed.* **2007**, *46*, 8074–8075. (j) Lalic, G.; Corey, E. J. *Org. Lett.* **2007**, *9*, 4921–4923. (k) Matsuo, J.; Takeuchi, K.; Ishibashi, H. *Org. Lett.* **2008**, *10*, 4049–4052. (l) Yeung, Y.-Y.; Corey, E. J. *Org. Lett.* **2008**, *10*, 3877–3878. (m) Tiefenbacher, K.; Mulzer, J. *Angew. Chem., Int. Ed.* **2008**, *47*, 2548–2555. (n) Nicolaou, K. C.; Pappo, D.; Tsang, K. Y.; Gibe, R.; Chen, D. Y.-K. *Angew. Chem., Int. Ed.* **2008**, *47*, 944–946. (o) Nicolaou, K. C.; Li, Ang; Edmonds, D. J.; Tria, G. S.; Ellery, S. P. *J. Am. Chem. Soc.* **2009**, *131*, 16905–16918. (p) McGrath, N. A.; Bartlett, E. S.; Sittihan, S.; Njardarson, J. T. *Angew. Chem., Int. Ed.* **2009**, *48*, 8543–8546. (q) Nicolaou, K. C.; Li, A.; Ellery, S. P.; Edmonds, D. *J. Angew. Chem., Int. Ed.* **2009**, *48*, 6293–6295. (r) Yun, S. Y.; Zheng, J.-C.; Lee, D. *J. Am. Chem. Soc.* **2009**, *131*, 8413–8415. (s) Ghosh, A. K.; Xi, K. *J. Org. Chem.* **2009**, *74*, 1163–1170. (t) Tiefenbacher, K.; Trondlin, L.; Mulzer, J.; Pfaltz, A. *Tetrahedron* **2010**, *66*, 6508–6513. (u) Eey, S. T.-C.; Lear, M. *J. Org. Lett.* ASAP, 10/29/10, DOI: 10.1021/ol102390t.

(4) (a) Beames, D. J.; Mander, L. N. *Aust. J. Chem.* **1971**, *24*, 343–351. (b) Beames, J. D.; Klose, T. R.; Mander, L. N. *Aust. J. Chem.* **1974**, *27*, 1257–1263, and 1269–1275. (c) Beames, D. J.; Klose, T. R.; Mander, L. N. *Chem. Commun.* **1971**, 773–774. (d) Morris, J. C.; Mander, L. N.; Hockless, D. C. *Synthesis* **1998**, 455–467.

(5) Buisson, D.; Cecchi, R.; Laffitte, J.-A.; Guzzi, U.; Azerad, R. *Tetrahedron Lett.* **1994**, *35*, 3091–3094.

allylic hydroperoxide.⁸ The stereochemistry of the newly introduced C-10 *sec*-hydroxyl group is the correct relative configuration.

Next, the possibility of selective reduction of the tetra-substituted dienone double bond in **10** by conjugate hydride reduction directed from the C-10 hydroxyl group was examined. Eventually, it was found that treatment of **10** with LiAlH₂(OEt)₂ in THF at -78 °C cleanly gave **12** (64%) and recovered starting material (30%), Scheme 3. The desired





Figure 3. ORTEP of **12**.

Scheme 3. Hydroxyl Directed Conjugate Reduction



stereochemistry at C-9 was confirmed by X-ray crystallography (Figure 3).

Despite the fact that **12** would appear to be readily converted into **13** by reported procedures,^{3a-c} treatment of **12** with trifluoroacetic acid in CH₂Cl₂ gave small amounts

of **13** and, interestingly, Epi-**12**. Since the ring cleavage of tetrahydrofurans with electrophilic reagents is well-known⁹ and forms the basis of the synthesis, for example, of 4-chlorobutanol from THF, it is somewhat surprising that **12/13** would be stable to strongly electrophilic reagents.

In consequence, we treated the 1,3-diol **12** with dimethylsulfoxide¹⁰ (as solvent, relatively neutral reaction conditions) under microwave conditions and obtained **13** in good yield.

The sequence of reactions from the known ketone **2** to **13** proceeds in five steps in an overall yield of 10% and is completely stereoselective.

Acknowledgment. The Welch Chair (F-0018) is thanked for their support of this work.

Supporting Information Available: Complete experimental details and compound characterization. This information is available free of charge via the Internet at <http://pubs.acs.org>.

OL102557K

(8) For rearrangements of allylic hydroperoxides, see: Beckwith, A. L.; Davies, A. G.; Davidson, I. G. E.; Maccoll, A.; Mruzek, M. H. *J. Chem. Soc., Perkin Trans 2* **1989**, 815–824.

(9) (a) Starr, D.; Hixon, R. M. *J. Am. Chem. Soc.* **1934**, *56*, 1595–1597.

(b) Starr, D.; Hixon, R. M. *Org. Syn. Coll. Vol. II*. **1943**, 571–572.

(10) Gillis, B. T.; Beck, P. E. *J. Org. Chem.* **1963**, *28*, 1388–1390.